Navigation Links
New England Journal of Medicine hails new skin cancer drug as 'greatest advance yet'
Date:6/13/2012

ssistant Professor in TGen's Integrated Cancer Genomics Division.

This Phase 2 study provided the efficacy data for vismodegib that led to its approval by the U.S. Food and Drug Administration (FDA) on Jan. 30, 2012.

"As a result of a strong collaboration between the Valley institutions, clinical development of this new medication, from the first clinical trial to the FDA approval, was led by the Valley researchers," said Dr. Sekulic, M.D and Ph.D., whose study found that vismodegib shrank advanced basal cell carcinoma tumors in 43 percent of patients with locally advanced disease and in 30 percent of patients whose disease spread to other organs.

The drug blocks the Hedgehog signaling pathway and was approved for treatment of locally advanced and metastatic basal cell carcinomas. Additional research noted encouraging results for patients with inherited genetic susceptibility for development of large numbers of BCC tumors, known as basal cell nevus syndrome.

"The availability of vismodegib and similar medications will really change the way we treat the patients with advanced forms of BCC, who had very limited options to date. In addition, this drug will likely offer a life-changing treatment for patients with basal cell nevus syndrome. It is possible that the drug may also be of benefit in treatment of earlier stages of BCC, and this is currently being evaluated in several clinical trials," Dr. Sekulic said.

"It is a landmark day for patients with basal cell carcinoma and all those involved in their care," said the NEJM editorial. However the editors cautioned that additional study of Hedgehog pathway inhibitors like vismodegib warrant further study so a larger number of patients may benefit.

FDA approval in five years is a remarkable achievement because clinical trials typically progress through three phases and can take up to 15 years to successfully complete, according to Mark Slater, Ph.D., Vice President of
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Red Tide Likely in New England This Season, Experts Warn
2. Elsevier, SVS announce 2013 launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
3. NAMS journal Menopause reflects on the WHI 10 years later
4. Reactions to HIV drug have autoimmune cause, reports AIDS journal
5. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
6. Journals and pharma collaborate on new recommendations
7. Model for breast cancer rehab featured in supplement to ACS journal, Cancer
8. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
9. Surgeon General receives 2012 Distinguished Public Service Award from internal medicine physicians
10. Nanomedicines promise fewer side effects in treating cancer
11. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... San Diego, CA (PRWEB) May 26, 2015 ... medical director, launched and directed a hospital-wide Patient Blood ... in Bangor that reduced overall blood usage by more ... five-year period. , Covered in detail in an ... PBM program resulted in substantially reduced perioperative red cell ...
(Date:5/26/2015)... CO (PRWEB) May 26, 2015 It ... diverse community foundation in Colorado. On Wednesday, May 13, ... ushered in a new era of community-based giving with ... Titled “Our Future in the Making,” the event celebrated ... The Denver Foundation to mobilize resources for good. , ...
(Date:5/26/2015)... Relias Learning , the leader in online ... services market, announces expansion of their user group sessions ... participation in 2014, they will double the number of ... an exciting new facelift. , Regional user group ... best practices, share their expertise, provide feedback directly to ...
(Date:5/26/2015)... 26, 2015 CIO Review has chosen ... Pharma and Life Sciences Technology Solution Providers. The positioning is ... compliant solution which is applicable across the entire security spectrum ... for broad adoption. , “SIGNiX has been on our ... Pharma and Life Sciences Technology space, and we are happy ...
(Date:5/26/2015)... Indosoft, Inc ., developer of ... DMi Partners contact center to Q-Suite 5.8 call ... contact center ACD system to drop Asterisk 1.4 support. ... trunk features as diversion headers, added Lyra support via ... to warm transfers to improve information handling ...
Breaking Medicine News(10 mins):Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3
... , CRANBURY, N.J., Sept. 10 Amicus ... and chief executive officer, John F. Crowley, will be presenting at the ... scheduled to begin on Monday, September 14 at 5:05 p.m. EDT. , ... the presentation by logging on to the Investors section of the Amicus ...
... Sept. 10 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: ... global life sciences markets, today reported financial results for the three-month ... million, a net loss of $62 million and a loss per ... $252 million in total revenue, a net loss of $10 million ...
... , , CAMBRIDGE, ... ISIS ) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ... Office (USPTO) has allowed an Isis patent application that further expands ... patent broadly covers methods of cleaving a target RNA via a ...
... , , , ST. ... ) announced that Novation, the leading health care supply contracting ... systems to its capital products contract portfolio. This is ... robotic interventional technology among Novation,s capital products offerings. This ...
... , SAN DIEGO, Sept. 10 The American ... to educate individuals and couples about their family-building options in a ... 21st. Those who attend Dessert & Learn La Jolla ... Law, about third party reproduction options like egg donation, sperm donation, ...
... (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology ... that disrupt the advance of life-threatening diseases, today announced ... drug target that combats breast cancer. , The target, ... death in breast cancer cells, thus curtailing development of ...
Cached Medicine News:Health News:MDS Reports Third Quarter 2009 Financial Results 2Health News:MDS Reports Third Quarter 2009 Financial Results 3Health News:MDS Reports Third Quarter 2009 Financial Results 4Health News:MDS Reports Third Quarter 2009 Financial Results 5Health News:MDS Reports Third Quarter 2009 Financial Results 6Health News:MDS Reports Third Quarter 2009 Financial Results 7Health News:MDS Reports Third Quarter 2009 Financial Results 8Health News:MDS Reports Third Quarter 2009 Financial Results 9Health News:MDS Reports Third Quarter 2009 Financial Results 10Health News:MDS Reports Third Quarter 2009 Financial Results 11Health News:MDS Reports Third Quarter 2009 Financial Results 12Health News:MDS Reports Third Quarter 2009 Financial Results 13Health News:MDS Reports Third Quarter 2009 Financial Results 14Health News:MDS Reports Third Quarter 2009 Financial Results 15Health News:MDS Reports Third Quarter 2009 Financial Results 16Health News:MDS Reports Third Quarter 2009 Financial Results 17Health News:MDS Reports Third Quarter 2009 Financial Results 18Health News:MDS Reports Third Quarter 2009 Financial Results 19Health News:MDS Reports Third Quarter 2009 Financial Results 20Health News:MDS Reports Third Quarter 2009 Financial Results 21Health News:MDS Reports Third Quarter 2009 Financial Results 22Health News:MDS Reports Third Quarter 2009 Financial Results 23Health News:Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology 2Health News:Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology 3Health News:Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology 4Health News:Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology 5Health News:Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology 6Health News:Stereotaxis Awarded Exclusive Contract by Novation for Robotic Interventional Technology 2Health News:Stereotaxis Awarded Exclusive Contract by Novation for Robotic Interventional Technology 3Health News:Stereotaxis Awarded Exclusive Contract by Novation for Robotic Interventional Technology 4Health News:Innovative Program Educates Hopeful Parents on Third Party Reproduction 2Health News:Innovative Program Educates Hopeful Parents on Third Party Reproduction 3Health News:GENova files patent for new breast cancer treatment 2
(Date:5/26/2015)... May 26, 2015 Boston Scientific Corporation (NYSE: ... 36 th Annual Global Healthcare Conference on June 9 ... Dan Brennan , executive vice president and chief ... Relations, will participate in a 35-minute question and answer session ... 10 a.m. PT. A live webcast of the ...
(Date:5/26/2015)... 2015 Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... President and Chief Executive Officer, will present at the ... at 8:30 a.m. ET in New York ... of the presentation will be available on the "Events ...
(Date:5/26/2015)... 26, 2015  Northstar Global Business Services, Inc. ... a deal with Mr. Checkout, a national distribution ... product, SNORenz to brick and mortar retail stores. ... cross section of about fifty convenience stores, pharmacies, ... valuable statistics during the lead time the company ...
Breaking Medicine Technology:Boston Scientific To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference 2Xencor to Present at Jefferies 2015 Healthcare Conference 2Northstar announces in-store rollout deal with national distribution group reaching more than 35,000 stores nationwide 2Northstar announces in-store rollout deal with national distribution group reaching more than 35,000 stores nationwide 3
... Nev., June 6, 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: ... for: The 2.00% Convertible Senior Notes due February ... 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes), ... due May 1, 2015 (the May 2015 Notes), effective June 6, ...
... 2011 Sanofi (EURONEXT: SAN and NYSE: ... REGN ) today announced that data showing that the ... significantly improved survival in previously treated metastatic colorectal cancer ... on Gastrointestinal Cancer on June 25, 2011.  The abstract ...
Cached Medicine Technology:PDL BioPharma Announces Conversion Rate Adjustments for its Convertible Notes 2ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 2ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 3ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 4ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 5ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 6ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients 7
Inquire...
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: